Literature DB >> 28501670

Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

Michelle L Ratay1, Andrew J Glowacki2, Stephen C Balmert1, Abhinav P Acharya2, Julia Polat3, Lawrence P Andrews4, Morgan V Fedorchak5, Joel S Schuman3, Dario A A Vignali6, Steven R Little7.   

Abstract

Dry eye disease (DED) is a common ocular disorder affecting millions of individuals worldwide. The pathology of DED involves the infiltration of CD4+ lymphocytes, leading to tear film instability and destructive inflammation. In the healthy steady state, a population of immunosuppressive T-cells called regulatory T-cells (Treg) regulates proliferation of immune cells that would otherwise lead to a disruption of immunological homeostasis. For this reason, it has been suggested that Tregs could restore the immunological imbalance in DED. To this end, one possible approach would be to recruit the body's own, endogenous Tregs in order to enrich them at the site of inflammation and tissue destruction. Previously, we have demonstrated a reduction of inflammation and disease symptoms in models of periodontitis corresponding to recruitment of endogenous Tregs, which was accomplished by local placement of controlled release systems that sustain a gradient of the chemokine CCL22, referred to here as Treg-recruiting microspheres. Given that DED is characterized by a pro-inflammatory environment resulting in local tissue destruction, we hypothesized that the controlled release of CCL22 could also recruit Tregs to the ocular surface potentially mediating inflammation and symptoms of DED. Indeed, data suggest that Treg-recruiting microspheres are capable of overcoming the immunological imbalance of Tregs and CD4+ IFN-γ+ cells in the lacrimal gland. Administration of Treg-recruiting microspheres effectively mitigated the symptoms of DED as measured through a number of outcomes such as tear clearance, goblet cells density and corneal epithelial integrity, suggesting that recruitment of endogenous Treg can mitigate inflammation associated with DED.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  CCL22; Drug delivery; Dry eye disease; Treg-recruiting microspheres; Tregs

Mesh:

Substances:

Year:  2017        PMID: 28501670      PMCID: PMC7805562          DOI: 10.1016/j.jconrel.2017.05.007

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  69 in total

1.  Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye.

Authors:  Min Joung Lee; Ah Young Ko; Jung Hwa Ko; Hyun Ju Lee; Mee Kum Kim; Won Ryang Wee; Sang In Khwarg; Joo Youn Oh
Journal:  Mol Ther       Date:  2014-08-25       Impact factor: 11.454

2.  Directed cell migration via chemoattractants released from degradable microspheres.

Authors:  Xiaojun Zhao; Siddhartha Jain; H Benjamin Larman; Sandra Gonzalez; Darrell John Irvine
Journal:  Biomaterials       Date:  2005-08       Impact factor: 12.479

Review 3.  Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research.

Authors:  Xin Zhou; Maren S Fragala; Janet E McElhaney; George A Kuchel
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-09       Impact factor: 4.294

4.  Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways.

Authors:  Xiaobo Zhang; Wei Chen; Cintia S De Paiva; Rosa M Corrales; Eugene A Volpe; Andrew J McClellan; William J Farley; De-Quan Li; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-08-09       Impact factor: 4.799

5.  Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor.

Authors:  F Gantner; M Leist; A W Lohse; P G Germann; G Tiegs
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

6.  Aqueous Tear Deficiency Increases Conjunctival Interferon-γ (IFN-γ) Expression and Goblet Cell Loss.

Authors:  Stephen C Pflugfelder; Cintia S De Paiva; Quianta L Moore; Eugene A Volpe; De-Quan Li; Koray Gumus; Mahira L Zaheer; Rosa M Corrales
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-11       Impact factor: 4.799

7.  Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye.

Authors:  Michael E Stern; Jianping Gao; Tammy A Schwalb; Mylinh Ngo; David D Tieu; Chi-Chao Chan; Brenda L Reis; Scott M Whitcup; Darby Thompson; Janine A Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-08       Impact factor: 4.799

8.  Therapeutic effects of topical doxycycline in a benzalkonium chloride-induced mouse dry eye model.

Authors:  Zhen Zhang; Wen-Zhao Yang; Zhen-Zhen Zhu; Qian-Qian Hu; Yan-Feng Chen; Hui He; Yong-Xiong Chen; Zu-Guo Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-06       Impact factor: 4.799

9.  In vitro expanded CD4+CD25+Foxp3+ regulatory T cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation.

Authors:  Karyn F Siemasko; Jianping Gao; Virginia L Calder; Rebecca Hanna; Margarita Calonge; Stephen C Pflugfelder; Jerry Y Niederkorn; Michael E Stern
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-24       Impact factor: 4.799

10.  Molecular mechanisms of treg-mediated T cell suppression.

Authors:  Angelika Schmidt; Nina Oberle; Peter H Krammer
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

View more
  19 in total

1.  Assessing the ocular surface microbiome in severe ocular surface diseases.

Authors:  Michael J Zilliox; William S Gange; Gina Kuffel; Carine R Mores; Cara Joyce; Paul de Bustros; Charles S Bouchard
Journal:  Ocul Surf       Date:  2020-07-24       Impact factor: 5.033

Review 2.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

3.  Engineering immunomodulatory biomaterials for type 1 diabetes.

Authors:  C L Stabler; Y Li; J M Stewart; B G Keselowsky
Journal:  Nat Rev Mater       Date:  2019-05-17       Impact factor: 66.308

4.  Inhibition of glycolysis in the presence of antigen generates suppressive antigen-specific responses and restrains rheumatoid arthritis in mice.

Authors:  Joslyn L Mangal; Sahil Inamdar; Tien Le; Xiaojian Shi; Marion Curtis; Haiwei Gu; Abhinav P Acharya
Journal:  Biomaterials       Date:  2021-08-20       Impact factor: 15.304

Review 5.  Visions of Eye Commensals: The Known and the Unknown About How the Microbiome Affects Eye Disease.

Authors:  Anthony J St Leger; Rachel R Caspi
Journal:  Bioessays       Date:  2018-10-05       Impact factor: 4.345

Review 6.  Engineering Immune Tolerance with Biomaterials.

Authors:  Joshua M Gammon; Christopher M Jewell
Journal:  Adv Healthc Mater       Date:  2019-01-03       Impact factor: 9.933

Review 7.  When Clarity Is Crucial: Regulating Ocular Surface Immunity.

Authors:  William Foulsham; Giulia Coco; Afsaneh Amouzegar; Sunil K Chauhan; Reza Dana
Journal:  Trends Immunol       Date:  2017-12-14       Impact factor: 16.687

8.  Treg-inducing microparticles promote donor-specific tolerance in experimental vascularized composite allotransplantation.

Authors:  James D Fisher; Stephen C Balmert; Wensheng Zhang; Riccardo Schweizer; Jonas T Schnider; Chiaki Komatsu; Liwei Dong; Vasil E Erbas; Jignesh V Unadkat; Ali Mübin Aral; Abhinav P Acharya; Yalcin Kulahci; Heth R Turnquist; Angus W Thomson; Mario G Solari; Vijay S Gorantla; Steven R Little
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-02       Impact factor: 11.205

9.  Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.

Authors:  Michelle L Ratay; Stephen C Balmert; Ethan J Bassin; Steven R Little
Journal:  Acta Biomater       Date:  2018-03-09       Impact factor: 10.633

Review 10.  Biologics and their delivery systems: Trends in myocardial infarction.

Authors:  Matthew A Borrelli; Heth R Turnquist; Steven R Little
Journal:  Adv Drug Deliv Rev       Date:  2021-03-26       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.